Thoughts Medication (MindMed) (NASDAQ:MNMD – Get Rating) and Mannatech (NASDAQ:MTEX – Get Rating) are each small-cap medical firms, however which is the superior funding? We are going to distinction the 2 firms primarily based on the energy of their threat, analyst suggestions, valuation, earnings, institutional possession, profitability and dividends.
Profitability
This desk compares Thoughts Medication (MindMed) and Mannatech’s web margins, return on fairness and return on property.
| Web Margins | Return on Fairness | Return on Property | |
| Thoughts Medication (MindMed) | N/A | -55.27% | -51.10% |
| Mannatech | 6.16% | 39.51% | 15.62% |
Insider and Institutional Possession
12.4% of Thoughts Medication (MindMed) shares are held by institutional traders. Comparatively, 32.0% of Mannatech shares are held by institutional traders. 45.8% of Mannatech shares are held by firm insiders. Robust institutional possession is a sign that hedge funds, massive cash managers and endowments consider a inventory will outperform the market over the long run.
Analyst Scores
It is a breakdown of current rankings and goal costs for Thoughts Medication (MindMed) and Mannatech, as reported by MarketBeat.com.
| Promote Scores | Maintain Scores | Purchase Scores | Robust Purchase Scores | Ranking Rating | |
| Thoughts Medication (MindMed) | 0 | 0 | 3 | 0 | 3.00 |
| Mannatech | 0 | 0 | 0 | 0 | N/A |
Thoughts Medication (MindMed) at the moment has a consensus goal value of seven.67, suggesting a possible upside of 882.91%. Given Thoughts Medication (MindMed)’s larger possible upside, analysis analysts clearly consider Thoughts Medication (MindMed) is extra favorable than Mannatech.
Earnings & Valuation
This desk compares Thoughts Medication (MindMed) and Mannatech’s gross income, earnings per share and valuation.
| Gross Income | Worth/Gross sales Ratio | Web Earnings | Earnings Per Share | Worth/Earnings Ratio | |
| Thoughts Medication (MindMed) | N/A | N/A | -$93.04 million | -0.23 | -3.39 |
| Mannatech | $159.76 million | 0.33 | $9.84 million | $4.72 | 5.76 |
Mannatech has larger income and earnings than Thoughts Medication (MindMed). Thoughts Medication (MindMed) is buying and selling at a decrease price-to-earnings ratio than Mannatech, indicating that it’s at the moment the extra reasonably priced of the 2 shares.
Abstract
Mannatech beats Thoughts Medication (MindMed) on 9 of the 11 components in contrast between the 2 shares.
About Thoughts Medication (MindMed) (Get Rating)
Thoughts Medication (MindMed) Inc., a medical stage biopharmaceutical firm, develops novel merchandise to deal with mind well being problems associated to psychiatry, habit, ache, and neurology. The corporate develops MM-120, which is in section 2 for the therapy of generalized nervousness dysfunction and a spotlight deficit hyperactivity dysfunction, in addition to for the therapy of persistent ache; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has accomplished section 1 for the therapy of opioid withdrawal. It additionally develops MM-402, a R-enantiomer of three,4-methylenedioxymethamphetamine for the therapy of core signs of autism spectrum dysfunction. The corporate is headquartered in Vancouver, Canada.
About Mannatech (Get Rating)
Mannatech, Integrated operates as a well being and wellness firm worldwide. It develops, markets, and sells dietary dietary supplements; topical and skincare, and anti-aging merchandise; and weight-management merchandise. The corporate primarily sells its merchandise instantly, in addition to via e-commerce and community advertising channels. Mannatech, Integrated was based in 1993 and is headquartered in Flower Mound, Texas.
Obtain Information & Scores for Thoughts Medication (MindMed) Each day – Enter your e-mail deal with under to obtain a concise each day abstract of the newest information and analysts’ rankings for Thoughts Medication (MindMed) and associated firms with MarketBeat.com’s FREE daily email newsletter.
